Philip Morris International (PM)
NYSEConsumer StaplesTobaccoSnapshot 2026-10-29
$208.79+0.14%
Close 2026-10-30 · 1-day change
NYSEConsumer StaplesTobaccoSnapshot 2026-10-29
Research Workspace
Put PM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Smoke-free product shipment volume growth: Direct metric needs a verified mapping.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPM’s claim rests on smoke-free products sustaining growth across its established business. Revenue growth slowed to 5.5% in Q3 2026 from 10.4% in Q2. Q3 non-GAAP earnings beat consensus by 2.6%. PM trades at 25× P/E versus a 16× peer median, reflecting expectations modest versus our view. The multiple premium must be earned, especially as reported profits are not well backed by cash. Our model puts the next-quarter miss probability near 15%. Smoke-free shipment growth remains under pressure because its direct metric needs verified mapping. Peer multiples imply a price roughly in line with where it trades (about fair); this read is provisional.
Trailing returns as of 2026-10-30. PM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering PM (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for PM in the last 4 months.
Continue this research
Compare PM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Tobacco — fair value, gap to price, and forward P/E.
Compare the value case
Put PM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Deliver organic net revenue growth of 5% to 7%
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $208.79
The last 12 months of price, then the range of analyst 12-month targets from today’s $208.79.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
5.5% revenue growth is within the 5%-7% objective, supported by smoke-free and combustible growth.
Advances: Achieve organic net revenue growth of 5% to 7% annually
Reported Q3 revenue growth, led by smoke-free products, supports organic revenue and smoke-free objectives.
Conflict-driven cost increases pressure earnings and may hinder growth and EPS objectives.
Advances: Increase adjusted diluted EPS by 9% to 11% excluding currency
2026 adjusted EPS forecast supports the EPS-growth objective despite increased ZYN investment.
Threatens: Increase adjusted diluted EPS by 9% to 11% excluding currency
Q3 beat is offset by conflict-related bottom-line pressure, challenging earnings growth.
Threatens: Increase adjusted diluted EPS by 9% to 11% excluding currency
Profit decline despite higher sales pressures earnings growth, though the headline lacks further context.
Threatens: Increase adjusted diluted EPS by 9% to 11% excluding currency
Estimate beat is tempered by cost pressures and a negative share reaction.
Advances: Achieve organic net revenue growth of 5% to 7% annually
Revenue and earnings exceeded estimates, supporting growth objectives.
